代謝相關(guān)脂肪性肝病是全球范圍內(nèi)肝病的主要原因，影響了全球近1/4的人口，尚無藥物獲批用于治療該病。從臨床前到臨床，多個制藥企業(yè)分別開展了針對抗代謝、抗凋亡和抗炎、抗纖維化等靶點的研究，取得了不同的結(jié)果?？偨Y(jié)上述不同靶點化合物在臨床II～III期的研究進展，闡明代謝相關(guān)脂肪性肝病治療藥物研發(fā)中的難點，提出可能的研究思路。

Metabolic-associated fatty liver disease (MAFLD) is the main cause of liver disease, which affected nearly one quarter of the world’s population, until now no drugs have been approved for the treatment of the disease. A lot of pharmaceutical companies have developed anti-metabolism, anti-apoptosis, anti-inflammatory or anti-fibrosis compounds for MAFLD treatment and showed different results from pre-clinical research to clinical research This article will summarize the research progress of these different target compounds in clinical phase II — III, clarify the difficulties in the development of therapeutic drugs for MAFLD, and propose possible research strategy.

R975